Herbies Headshop

Medical Cannabis News & Information

National Cancer Institute: Cannabis Has Antitumor Capabilities, is Also an Appetite Stimulant and Painkiller

on . Posted in Medical Cannabis News & Information

In claims that are in vast contrast to those of the Drug Enforcement Administration and other government entities, the government-funded National Cancer Institute has a report published on its website which proclaims several benefits of cannabis and cannabinoids, citing numerous scientific studies to back their claims. The page was updated as recently as August.

The report starts by explaining what cannabinoids are; “Cannabinoids are a group of 21-carbon–containing terpenophenolic compounds produced uniquely by Cannabis sativa and Cannabis indica species”, the report continues, “These plant-derived compounds may be referred to as phytocannabinoids. Although delta-9-tetrahydrocannabinol (THC) is the primary psychoactive ingredient, other known compounds with biologic activity are cannabinol, cannabidiol (CBD), cannabichromene, cannabigerol, tetrahydrocannabivarin, and delta-8-THC. CBD, in particular, is thought to have significant analgesic and anti-inflammatory activity without the psychoactive effect (high) of delta-9-THC.”

GW Pharmaceuticals Announces Successful Closing of Mutual Recognition Procedure for Sativex in France

on . Posted in Medical Cannabis News & Information

London, UK; 21 October 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the successful closing of the European Mutual Recognition Procedure (MRP) in France for Sativex® oromucosal spray in the treatment of spasticity due to Multiple Sclerosis (MS) and a resulting recommendation for approval by the French authorities.

FDA Approves Investigational Trials Assessing Cannabidiol For Pediatric Epilepsy

on . Posted in Medical Cannabis News & Information

Washington, DC: The US Food and Drug Administration has approved two clinical trials to assess the efficacy of cannabidiol (CBD), a nonpsychoactive plant cannabinoid, in the treatment of intractable pediatric epilepsy. The two approved trials will take place at New York Medical School and at the University of California at San Francisco, according to an online report in the journal O'Shaughnessy's. The cannabidiol formulations in the trials will be provided by British biotechnology firm GW Pharmaceuticals, which produces organic cannabinoid extract medicines, including Sativex.

Study shows non-hallucinogenic cannabinoids are effective anti-cancer drugs

on . Posted in Medical Cannabis News & Information

New research has shown that the non-hallucinogenic components of cannabis could act as effective anti-cancer agents.

The anti-cancer properties of tetrahydrocannabinol (THC), the primary hallucinogenic component of cannabis, has been recognised for many years, but research into similar cannabis-derived compounds, known as cannabinoids, has been limited.

The study was carried out by a team at St George’s, University of London. It has been published in the journal Anticancer Research.

Study Finds Cannabis Protects Against Sepsis

on . Posted in Medical Cannabis News & Information

According to a study published earlier this year by the National Institute of Health, activation of the body’s cannabinoid receptors – something which cannabis does naturally – can protect against sepsis, a serious inflammatory illness which is due to a severe reaction to bacteria or germs, which often proves fatal.

During the study, which used mice subjects, researchers found that activation of the cannabinoid receptor 2 (CB2R) can “significantly extend the survival rate and decrease serum proinflammatory cytokines” in those with sepsis.